SUPERNUS PHARMACEUTICALS INC

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

SUPN$27.62+5.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Earnings

(in thousands, except share and per share data)

	Year Ended December 31,
	2024	2023	2022
Revenues
Net product sales	$637,696	$573,933	$649,432
Royalty, licensing and other revenues	24,121	33,588	17,806
Total revenues	661,817	607,521	667,238
Costs and expenses
Cost of goods sold(a)	77,906	83,779	87,221
Research and development	108,796	91,593	74,552
Selling, general and administrative	321,582	336,361	377,221
Amortization of intangible assets	77,977	82,385	82,630
Intangible asset impairment charges	—	20,189	—
Contingent consideration gain	(6,110)	(1,517)	(510)
Total costs and expenses	580,151	612,790	621,114
Operating earnings (loss)	81,666	(5,269)	46,124
Other income (expense)
Interest and other income, net	16,204	10,453	21,689
Interest expense	—	(2,415)	(7,070)
Total other income (expense), net	16,204	8,038	14,619
Earnings before income taxes	97,870	2,769	60,743
Income tax expense	24,005	1,453	32
Net earnings	$73,865	$1,316	$60,711
Earnings per share
Basic	$1.34	$0.02	$1.13
Diluted	$1.32	$0.02	$1.04
Weighted average shares outstanding
Basic	55,100,063	54,536,281	53,665,143
Diluted	55,958,537	55,506,828	61,679,800

(a) Excludes amortization of intangible assets.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.